Scarica l'app Stockscreener
0.2437
9.41%
-0.0253
Pre-mercato:
.25
0.0063
+2.59%
Precedente Chiudi:
$0.269
Aprire:
$0.2627
Volume 24 ore:
1.48M
Relative Volume:
1.09
Capitalizzazione di mercato:
$29.93M
Reddito:
$1.29M
Utile/perdita netta:
$-29.87M
Rapporto P/E:
-0.6769
EPS:
-0.36
Flusso di cassa netto:
$-14.70M
1 W Prestazione:
-18.08%
1M Prestazione:
-26.40%
6M Prestazione:
-61.67%
1 anno Prestazione:
-56.87%
Intervallo 1D:
$0.24
$0.2711
Intervallo di 1 settimana:
$0.24
$0.31
Portata 52W:
$0.24
$0.94
VolitionRX Ltd Stock (VNRX) Company Profile
Nome
VolitionRX Ltd
Settore
Industria
Telefono
646 650 1351
Indirizzo
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Confronta VNRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.2437 | 33.03M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
575.91 | 215.01B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
228.53 | 159.87B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
700.55 | 56.23B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
140.60 | 39.54B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
223.63 | 37.85B | 15.90B | 1.28B | 2.21B | 7.2842 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2023-02-01 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-02-17 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-03-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-05-16 | Iniziato | Maxim Group | Buy |
| 2018-05-14 | Reiterato | The Benchmark Company | Buy |
| 2016-09-07 | Reiterato | Rodman & Renshaw | Buy |
| 2016-02-01 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
VolitionRX Ltd Borsa (VNRX) Ultime notizie
VolitionRx announces new paper on Capture-Seq, achieves 180-fold enrichment - MSN
VolitionRx to eliminate veterinary CEO role as part of cost-realignment - Investing.com Australia
VolitionRx Announces Termination of CEO Position at Subsidiary - TradingView — Track All Markets
VolitionRx (VNRX) to end Volition Veterinary CEO role, retain Dr. Butera as consultant - Stock Titan
VolitionRx (VNRX) Unveils Innovative Cancer Detection Method - GuruFocus
Volition (NYSE AMERICAN: VNRX) posts 100% sensitivity in 70-person liquid biopsy study - Stock Titan
VolitionRx’s (VNRX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
VolitionRx downgraded to Hold from Buy at Maxim - MSN
Why VolitionRX Limited stock is a strong buy call2025 Pullback Review & Risk Controlled Daily Plans - Newser
VolitionRx’s Sepsis Biomarker Selected for French National Healthcare Initiative - citybuzz
VolitionRX (VNRX): Analyst Maintains 'Buy' Rating Amidst Stable Price Target | VNRX Stock News - GuruFocus
VolitionRx (NYSE AMERICAN: VNRX) named sole biomarker partner in €6.3M DETECSEPS sepsis detection program - Stock Titan
How VolitionRx Limited stock valuations compare to rivalsGap Up & Fast Entry Momentum Trade Alerts - Newser
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis - Yahoo Finance
VolitionRx (NYSE:VNRX) Lowered to “Hold” Rating by Maxim Group - Defense World
How VolitionRx Limited stock reacts to job market data2025 Market Sentiment & Consistent Growth Equity Picks - Newser
VNRX: Maxim Group Downgrades VolitionRX to Hold | VNRX Stock New - GuruFocus
Healthy Upside Potential: VolitionRX Ltd (VNRX) - Setenews
VolitionRx (VNRX) Insider Trading Activity 2025 - MarketBeat
VolitionRX (VNRX) Analyst Rating Update: Maintain 'Buy' with $5 Target | VNRX Stock News - GuruFocus
VolitionRX Ltd (VNRX) is looking forward to a strong quarter - Setenews
VolitionRx (VNRX) Stock Surges with First Sale of Nu.Q Cancer Assays to European Cancer Center - parameter.io
VolitionRx announces first sale of Nu.Q Cancer assays to French hospital - Investing.com India
VolitionRx announces first sale of Nu.Q Cancer assays to French hospital By Investing.com - Investing.com South Africa
Nu.Q Cancer Assays Sold for Certification at Lyon Center, VolitionRx (NYSE: VNRX) - Stock Titan
Freedom Capital Markets lowers VolitionRX stock price target on delayed revenue growth - Investing.com Australia
Freedom Capital Markets lowers VolitionRX stock price target on delayed revenue growth By Investing.com - Investing.com South Africa
Can VolitionRX Limited stock sustain breakout momentumEarnings Risk Report & Stepwise Trade Execution Plans - newser.com
Will VolitionRX Limited stock beat international competitionQuarterly Earnings Summary & Capital Efficient Trading Techniques - newser.com
What makes VolitionRx Limited stock attractive to growth fundsJuly 2025 Retail & Accurate Trade Setup Notifications - newser.com
Smart tools for monitoring VolitionRx Limited’s price actionWeekly Market Summary & Reliable Breakout Stock Forecasts - newser.com
How strong is VolitionRx Limited stock balance sheet2025 Major Catalysts & Safe Capital Growth Plans - newser.com
How VolitionRX Limited stock trades after rate cutsQuarterly Performance Summary & Expert-Curated Trade Recommendations - newser.com
H.C. Wainwright lowers VolitionRX stock price target on valuation update By Investing.com - Investing.com Nigeria
Are Smart Investors Making the Right Decision? VolitionRX Ltd (VNRX) - Setenews
H.C. Wainwright lowers VolitionRX stock price target on valuation update - Investing.com
VolitionRx price target lowered to $1.50 from $2.50 at H.C. Wainwright - MSN
Reynolds, Volitionrx CEO, buys $7,000 in VNRX stock By Investing.com - Investing.com Nigeria
Reynolds, Volitionrx CEO, buys $7,000 in VNRX stock - Investing.com
CEO Reynolds Buys 20,000 ($7K) Of VolitionRX Ltd [VNRX] - TradingView
[Form 4] VOLITIONRX LTD Insider Trading Activity - Stock Titan
VolitionRX (VNRX) Target Price Lowered by HC Wainwright & Co. | - GuruFocus
VolitionRX (VNRX): Analyst Jason Kolbert Reaffirms Buy Rating wi - GuruFocus
VolitionRx Limited Reports Q3 2025 Financial Growth - MSN
VolitionRx Ltd. Earnings Call Highlights Growth and Partnerships - The Globe and Mail
Using Ichimoku Cloud for VolitionRx Limited technicalsLong Setup & Detailed Earnings Play Alerts - newser.com
Is VolitionRX Limited stock resilient in recession scenariosSell Signal & High Return Trade Opportunity Guides - newser.com
VolitionRx Limited (AMEX:VNRX) Q3 2025 Earnings Call Transcript - Insider Monkey
VolitionRX Ltd Azioni (VNRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.04%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):